Ukunciphisa iMpawu ze-Irritable Bowel Syndrome
I-Viberzi (eluxadoline) yonyango evunyiweyo yi-US Food and Drug Administration (FDA) yokunyangwa kwehudo-ebalulekileyo kwi-IBS (IBS-D) kubantu abadala. I-Viberzi yenzelwe ukuba isebenze kwindawo yangasese kwindlela yokutya yokunceda ukulawula isifo sohudo kunye nokunciphisa iintlungu zesisu ngenxa yesifo.
Nangona oogqirha bengacacanga ngokupheleleyo oko kubangela iimpawu eziphindaphindiweyo ze-IBS (kubandakanywa iintlungu zesisu, ukucubungula, i-gas, isifo sohudo, okanye ukutyikitya), i-Viberzi iyakwazi ukubonelela izibonelelo kubantu abangenayo impendulo kwi-anti-diarralal agents.
Indlela iViberzi isebenza ngayo
I-Viberzi ifumaneka ngogunyaziso kwaye yenzelwe ukuthathwa ngomlomo, kabini imihla ngemihla, ngokutya. Iza kumabini ama-75-milligram kunye ne-100-milligram yefayili ephetshwe ngefilimu.
I-Viberzi isebenza ngokusebenza okanye ukuphazamisa i-opioid receptors ezahlukeneyo kwindlela yokugaya. Lawa awamkelekileyo abandakanyekayo kwi- gut motility , intlungu yesifo, kunye nokukhutshwa kwamanzi emathumbu. I-Viberzi iyingqayizivele kuba ivuselela iintlobo ezimbini ze-receptor kwaye inqanda omnye, ukubonelela ngaphandle kokuqhaqha.
Ezi zinto zifumana imisebenzi eyahlukileyo neyodwa:
- I-Mu receptors inoxanduva lokusondeza umthambo (ukutshatyalaliswa kwezihlunu zesisu).
- I-Kappa receptors inqanda ukuchasana kwamakholoni.
- Ii-receptor zeDelta zidibanisa izibilini zamathumbu.
Ukongezwa kwe-receptor antagonist iyona nto ibalulekileyo ekukhuseleni ukumbathisa okubonwayo kunye nezinye iziyobisi ezifana ne- imodium (loperamide) kunye neLomotil (i-atropine / diphenoxylate) echaphazela kuphela i-mumu ne-kappa receptors.
I-FDA ivumile iViberzi ngokusekelwe kwizilingo ezimbini zezifundo zeSigaba III ezigqityiweyo ukuba izilwanyana zanikezela ukuphucula okuthobekileyo kwixesha kunye nokuphuthuma kokunyuka kwezilwanyana kunye nokuphucuka okuthobekileyo kwintlungu esiswini kunye nesigxina.
Imiphumo emibi yeziyobisi
Imiphumo emibi yeViberzi yimizimba yesisu kodwa inokuchaphazela ezinye iinkqubo ngenxa yemiphumo ye-opioid.
Kwezinye iimeko, iimpawu zesilwayo zingabangela ukuba nabo bafana ne-IBS. Phakathi kwezinye zeziphumo eziqhelekileyo ezichaphazelekayo:
- I sizathu
- Intlungu zesisu
- Usulelo oluphezulu lokuphefumula
- Ukuvutha
- Runny okanye impumlo ephihliweyo
- Ukuqhawula
- Bronchitis
- Utywala
- Gesi
- Rash
- Ukukhathala
Iimpembelelo ze-opioid zinokuthi zichaphazele i- sphincter ye-Oddi (i-valve ngelixa ilawula i-bile kunye ne-pancreatic fluid emathumbu). Ukuba oko kwenzeka, i- pancreatitis iyakhula .
Ngaloo ndlela, i-Viberzi ayikwazi ukunyulwa kubantu abangenayo i-gallbladder (ilungu elivelisa ibhili) okanye abane-pancreatitis, ukukhubazeka kwesibindi, ukuvinjelwa kwe-bile, okanye ukuxhalabisa okukhulu. Izibhedlele kunye nokufa ziye zabikwa kubantu abangenalo i-gallbladder ezithatha ezimbalwa njengezixhobo ezimbini zeViberzi.
Kufuneka kwakhona kugwenywe kubantu abaphuza ngaphezu kotywala kotywala ngosuku.
Isibisi se-opioid, iViberzi inakho ukusetyenziswa kakubi kunye / okanye kuxhomekeke kuyo. Kufuneka kusetyenziswe kuphela phantsi kweliso logqirha. Nangona iziphumo ziphantsi kakhulu kune-Oxycontin (oxycodone), kunokubangela ukuba utywala xa uxhatshazwa kwaye uxhomekeke ekuxhomekeke kwe-opioid.
> Imithombo:
> Davenport, J .; Covington, P .; Bonifacio, L. et.al. "Impembelelo yokufumana abathumeli be-OAT3 kunye ne-OATP1B1 kunye ne-efflux transporter MRP2 kwi-pharmacokinetics ye-eluxadoline." J Clin Pharmacol. 2015; 55: 534-42. INGXELO: 10.1002 / jcph.442.
> Ihobe, L .; Lembo, A .; Randall, C. et.al. "I-Eluxadoline Izibonelelo Ezigulane Ne-Irritable Bowel Syndrome I-Dwarrhea kwiSifundo seSigaba sesi-2." Gastroenterology 2013; 145: 329-38. INGXELO: 10.1053 / j.gastro.2013.04.006.
> Ulawulo lweZiko lokuTya kunye neDrug. "I-FDA ilumkisa malunga nobungozi obunzulu be-pancreatitis kunye neziyobisi ezigwenxa iViberzi (eluxadoline) kwizigulane ezingenayo i-gallbladder." Silver Spring, eMaryn; kukhutshwa ngoAgasti 2016.